Advancing the Future of Medicine with NanoCont™

At MAA Laboratories, we are redefining pharmaceutical innovation through NanoCont™—a next-generation, nanoparticle-based drug delivery and continuous manufacturing platform designed to enable clinically differentiated therapies with enhanced absorption, improved tolerability, patient-friendly dosage forms, and scalable, cost-efficient production.

NanoCont™ is engineered to address some of the most complex challenges in drug development and delivery. Its unique integration of advanced nanotechnology with continuous manufacturing offers exceptional formulation flexibility, dose optimization, and manufacturing consistency—making it applicable across a wide range of therapeutic areas and dosage forms.

Multiple NanoCont™-enabled drug products are currently in development, with their clinical strategies and study designs approved by the U.S. FDA. These milestones reflect strong alignment with regulatory expectations and validate the platform’s readiness for clinical advancement and global scalability.

The NanoCont™ platform is patented in major global markets, including the United States, with additional applications pending worldwide. It has been officially recognized by the U.S. FDA’s Emerging Technology Programand reviewed by multiple divisions within the FDA, as well as by regulatory authorities in Europe and Canada. We are actively expanding regulatory engagement across additional global markets.

At MAA Laboratories, our mission is to bring NanoCont™-enabled therapies to patients worldwide—delivering innovation that is regulatory-ready, clinically impactful, and commercially scalable.

? Discover how NanoCont™ is transforming drug development—and powering the next generation of life-changing medicines.